Physicians often use sitagliptin and Januvia “interchangeably”, says MSD India’s managing director Rehan Khan describing the strong recall that the DPP-4 inhibitor commands in the country amid a groundswell of generic competition on the Indian market.
MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent
MSD India managing director Rehan Khan talks to Scrip about price adjustments for Januvia and the brand’s strong physician recall amid a tsunami of competition post loss of exclusivity, as also plans for Gardasil, which faces upcoming competition from Indian vaccines star Serum Institute. He also signals huge strides made by Keytruda, now the top cancer therapy in the country.
More from Business
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.